A Single-center Retrospective Analysis of the Effect of Radium-223 (Xofigo) on Pancytopenia in Patients with Metastatic Castration-resistant Prostate Cancer

Introduction Radium-223 (Xofigo, Bayer Pharmaceuticals Inc., Whippany, NJ) has been shown to increase overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC), via the phase 3 ALpharadin in SYMPtomatic Prostate CAncer (ASLYMPCA) study. Hematologic side effects of rad...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cureus
Autors principals: Skelton, William P, Dibenedetto, Samantha W, Pang, Shiyi S, Pan, Kelsey, Barish, Jacob L, Nwosu-Iheme, Adaeze, Dang, Long
Format: Artigo
Idioma:Inglês
Publicat: Cureus 2020
Matèries:
Oncology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7047342/
https://ncbi.nlm.nih.gov/pubmed/32140364
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.6806
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars